+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 69 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.

Age: 50Years - 85YearsAll GendersPhase 2
80 locations
T

Actively Recruiting

Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.

Age: 18Years +All GendersPhase 1Phase 2
86 locations
P

Actively Recruiting

Researchers are evaluating ZE94-0605, an oral selective cyclin-dependent kinase 2 CDK2 inhibitor, in adults with advanced, unresectable, or metastatic solid tumors that have not responded to or are intolerant of existing therapies. This first-in-human, open-label Phase 1 study consists of two parts Phase 1a to find the highest safe dose and biologically effective dose through sequential dose escalation, and Phase 1b to randomize participants with specific molecular features such as CCNE1 amplification to determine the recommended Phase 2 dose. ZE94-0605 is given orally once daily in a fasted state in continuous 28-day cycles. Phase 1a explores doses from 50 mg optional up to 650 mg or higher if needed, while Phase 1b randomizes about 30 participants to receive either the maximum tolerated dose or one dose level below it. Treatment continues until disease progression, unacceptable side effects, withdrawal, or completion of 26 cycles. Participants will undergo regular assessments including response evaluations before dosing on several cycle days, detailed pharmacokinetic and biomarker testing during early cycles, and circulating tumor DNA analysis at multiple timepoints. Researchers will monitor safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity. The study duration may extend up to approximately 24 months with ongoing monitoring and follow-up.

Age: 18Years +All GendersPhase 1
3 locations
L

Actively Recruiting

Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.

Age: 18Years +All GendersPhase 3
118 locations
B

Actively Recruiting

Researchers are conducting the BALANCE platform trial to study different treatment strategies for Gram-negative bloodstream infections GN BSIs. This adaptive trial addresses important questions about managing these infections, which have high risks and are complicated by increasing antibiotic resistance. The trial builds on previous research and aims to improve treatment approaches and patient outcomes while addressing antimicrobial resistance challenges. Participants in the trial receive various treatments depending on the domain they are assigned to. These include strategies such as antibiotic de-escalation or continuation, use of oral beta-lactams versus non-beta-lactams, decisions about replacing or retaining central vascular catheters, comparison of cephalosporins versus carbapenems for certain bacteria, and whether to perform routine follow-up blood cultures. The trial is open-label and embedded in routine hospital care, with an adaptive design that allows adding or removing treatment domains over time. During the study, participants undergo regular evaluations including monitoring for death, reinfection, readmission, and development of antimicrobial resistance over 90 days. The main measurement used is the Desirability of Outcome Ranking DOOR scale. Interim analyses occur frequently to assess results and determine continuation. Participation includes hospital admission, treatment under routine care with study interventions, and follow-up for outcome assessments. The study is planned to continue until April 2028 and enrolls patients from newborns to elderly adults.

Age: 0Years - 130YearsAll GendersPhase Not Applicable
39 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, recommended dose, and preliminary effectiveness of BGB-11417, a drug taken by mouth, alone and combined with azacitidine, in patients with acute myeloid leukemia AML, myelodysplastic syndrome MDS, or MDSmyeloproliferative neoplasm MPN. This study aims to find the best dose for further testing and to explore how these treatments work together. It is an open-label trial sponsored by BeOne Medicines, including Phase 1b and Phase 2 parts. Participants with AML or MDS will receive BGB-11417 and azacitidine in 28-day treatment cycles. Azacitidine is given by injection or under the skin for 7 days per cycle, while BGB-11417 is taken orally for varying days per cycle, depending on the group. Some participants will have a modified second treatment cycle to study interactions with posaconazole, an oral drug given for 8 days during that cycle. A specific group in China with MDS or relapsedrefractory AML will receive BGB-11417 alone on a 28-day cycle. During the study, participants will be closely monitored for side effects, treatment effects, and drug levels in their blood. Assessments include tracking dose-limiting toxicities and adverse events for up to 24 months. Response to treatment will be measured by remission rates and other markers of blood health. Researchers will also examine how the drugs interact in the body. Participants will undergo regular visits and tests to evaluate safety and treatment impact throughout the study period, which may last up to several years until study completion in 2028.

Age: 18Years +All GendersPhase 1Phase 2
47 locations
P

Actively Recruiting

Researchers are evaluating the combination of bleximenib with venetoclax VEN and azacitidine AZA compared to placebo with VEN and AZA alone for treating adults newly diagnosed with Acute Myeloid Leukemia AML who have specific gene mutations in NPM1 or KMT2A. This phase 3 randomized, double-blind study is designed for participants ineligible for intensive chemotherapy, aiming to understand how these treatments work in this population. Participants will receive treatment in 28-day cycles until disease progression or unacceptable side effects occur. One group will take oral bleximenib alongside oral venetoclax and intravenous or subcutaneous azacitidine, while the other group receives a placebo plus venetoclax and azacitidine. Treatment continues with regular cycles, and the study monitors effects over time. Throughout the study, participants will be assessed for response, including complete remission rates and overall survival, for up to more than four years. Researchers will also track event-free survival, duration and timing of remission, transfusion independence, adverse events, and blood levels of bleximenib. Safety and laboratory tests will be conducted regularly to monitor participant health and treatment effects.

Age: 18Years +All GendersPhase 3
270 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of combining ficlatuzumab with cetuximab compared to cetuximab alone in people with recurrent or metastatic RM HPV-negative head and neck squamous cell carcinoma HNSCC. This Phase 3, randomized, double-blind, placebo-controlled study focuses on participants who have not responded to prior anti-PD-1PD-L1 immune checkpoint inhibitors and platinum-based chemotherapy. The goal is to see if adding ficlatuzumab improves survival outcomes in this patient group. Participants are assigned to one of three groups two groups receive different doses of intravenous ficlatuzumab plus cetuximab on days 1 and 15 of each 28-day cycle, while the third group receives a placebo plus cetuximab on the same schedule. The study will enroll about 410 participants and compare progression-free survival and overall survival among these groups. Treatment cycles continue until disease progression or other study endpoints. During the study, participants will undergo regular imaging scans CT or MRI to assess tumor response every 8 weeks during the first year, then every 12 weeks in years 2 and 3, and every 6 months thereafter. Researchers will monitor safety, quality of life, and immune responses, including antidrug antibodies. The study period spans approximately 44 months with ongoing evaluations from randomization until death or last response assessment.

Age: 18Years +All GendersPhase 3
112 locations
S

Actively Recruiting

Researchers are studying how well Immune Globulin Infusion IGI, 10% can help prevent infections in adults with multiple myeloma who are receiving a special bispecific antibody therapy targeting B-cell maturation antigen BCMA and CD3. The trial compares two groups one receiving IGI, 10% regularly for 12 months as primary infection prevention, and the other receiving IGI, 10% only if they develop a serious infection during the study period. This is a Phase 3, randomized, open-label study sponsored by Takeda. Participants will be randomly assigned to either receive IGI, 10% intravenously every 3 or 4 weeks for 12 months regardless of infections or receive it only after experiencing at least one serious infection during the 12-month observation. The dosing is based on standard care, with a dose of 400 mgkg given within 3 days after randomization. The study design includes 15 to 19 clinic visits depending on dosing intervals. During the study, participants will be monitored for serious infections and other infection-related outcomes up to 12 months. Researchers will measure the time to first serious infection as the primary outcome, along with rates of infections, antibiotic use, hospitalizations, and immune response markers such as immunoglobulin G levels. Safety will also be assessed by tracking adverse events related to IGI, 10%. Total participation lasts up to 14 months including an approximately 8-week screening period.

Age: 18Years +All GendersPhase 3
65 locations

1-10 of 69

1